anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In three adult SCD centers, we will conduct a prospective cohort study to test the primary hypothesis that the incidence of infarct recurrence (stroke or silent stroke) or new strokes in adults with silent strokes treated with hydroxyurea will be greater than in those without strokes treated with hydroxyurea. We will test two secondary hypotheses: 1) adults with SCD and silent strokes have cognitive morbidity when compared to adults with SCD without silent strokes, and 2) adults with SCD and strokes receiving regular blood transfusion will have a higher incidence of infarct recurrence than those with SCD without strokes. The aims include Aim 1: Compare the incidence of new overt and silent strokes in adults with SCD and silent strokes to a comparison group of adults without silent strokes or overt strokes. Aim 2: Compare the cognitive morbidity of those with silent strokes and overt strokes to those without strokes. Aim 3: Compare the incidence of new overt and silent stroke in adults with SCD and overt strokes receiving transfusion to adults with SCD without silent or overt strokes treated with hydroxyurea. All clinical information and neuroimaging will be centrally adjudicated with masked and experienced neurology and neuroradiology committees. Data generated after completion of this proposal are critical for developing the first-ever phase III trials for secondary stroke prevention therapies in adults with SCD.
PURPOSE: We aimed to assess knowledge, attitudes, and perceived barriers among health care professionals (HCPs), policymakers, and regulators in Vietnam related to opioid therapy for cancer pain.
METHODS: We conducted a cross-sectional study in Vietnam from June to August 2022. Participants completed a questionnaire on their demographic characteristics, knowledge and attitudes toward opioid therapy, and barriers to accessing opioids for cancer pain.
RESULTS: Two hundred seven HCPs and 15 policymakers/regulators completed the questionnaire. Poor knowledge about opioids in cancer pain was found in 63.3% of HCPs and 80.0% of policymakers/regulators. Poor knowledge was associated with a lack of training in cancer pain management or palliative care (PC; prevalence ratio [PR], 1.14 [95% CI, 1.04 to 1.24]). Negative attitudes toward opioid therapy in cancer pain were held by 64.7% of HCPs and 80.0% of policymakers/regulators. Negative attitudes were associated with the unavailability of oral morphine in the workplace (PR, 1.10 [95% CI, 1.01 to 1.20]). The most common major barriers reported were the absence of national policy on pain management and PC (34.7%), inadequate training in opioid use for cancer pain (33.8%), lockdown of health facilities during the COVID-19 pandemic (32.4%), limited opioid availability in local health facilities (32.4%), and excessively restrictive regulation of opioid dispensing in pharmacies (32.4%).
CONCLUSION: This study found a knowledge deficit and negative attitudes toward opioid therapy for cancer pain among HCPs and policymakers/regulators. Improving education and training in opioid therapy is essential. Recognizing major barriers can guide strategies to enhance safe opioid accessibility for cancer pain management in Vietnam.
PROBLEM TO BE SOLVED: To prepare a composition for external use, containing a specific glycoside, highly safe for skins and exhibiting a skin-beautifying effect and a figure-thinning effect only by applying a simple treatment to a body. SOLUTION: This composition for external use contains a glycoside of the formula (G is a group selected from monosaccharide residues and oligosaccharide residues; R is a 8-11C linear or branched, saturated or unsaturated hydrocarbon group). The glycoside of the formula is compounded in an amount of approximately 0.05-5.0wt.%. The glycoside of the formula is obtained by condensing nonylic acid vanillylamide with an acetylated saccharide in the presence of a catalyst such as boron trifluoride or phosphorus oxychloride and subsequently deacetylating the reaction product in the presence of an alkali. The glycoside of the formula is e.g. nonylic acid vanillylamide-D-glucoside (α or β-isomers) or nonylic acid vanillylamide-D-galactoside (α or β-isomer).
PURPOSE: To provide pharmaceuticals which consist of specific phenyl pyrazoles and phenyl isothiazoles as effective components and are used to treat an inflammatory intestinal disease or to prevent the recurrence thereof and to lessen the danger of a cancer. CONSTITUTION: The pharmaceuticals consist of the compd. of the formula [X is S, N, methyl substd. N; R is H, amino, a 1 to 3C alkylamino, OH; R<1> is OH, OM (M is nontoxic cation); R<2> , R<3> are H, a halo, a 1 to 3C alkyl, trifluoromethyl, a 1 to 3C alkoxy] as the effective components and are used as the medicine for treating the inflammatory intestinal disease and for prevention of the recurrence thereof. The pharmaceuticals contg. the compd. of the formula I in particular are for topical administration, such as suppository and enema, suitable for rectal administration. The compd. of the formula I is, for example, sodium 3-(3-trifluoromethylphenyl)-4-aminopyrazole-5-carboxylate, tetraethylammonium 3-(3-chloro-4-methylphenyl)isothiazole-5-carboxylate, etc. The medicine particularly prevents the colorectal cancer and prevents the recurrence thereof.
Investigators seek to determine if an online based intervention can be developed to target increases in childhood sleep. The primary objectives of this study are to determine if different messaging strategies lead to the longer sleep duration.Children aged 9-12 who sleep about 6-8.5 hours per night will wear a Fitbit for 11 weeks in order to measure sleep patterns. Participants will have a sleep goal to meet each night. Participants will be randomized to one of thirty-two study conditions and receive text and/or email messaging. Some study arms receive additional messaging with different content and frequency of delivery. The study involves one visit to the Children's Hospital of Philadelphia (CHOP).
Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
BACKGROUND: During the COVID-19 pandemic, the Chinese government implemented nationwide public health interventions to control its spread. However, the impact of these measures on other infectious diseases remains unclear.
METHODS: The incidence of three types of notifiable infectious diseases in China were analyzed between 2013 and 2021. The seasonal Mann-Kendall test and Mann-Kendall mutation test were employed to examine trends and mutations in the time series. Based on the counterfactual inference, historical incidence rates were employed to construct SARIMA models and predict incidence between January 2020 and December 2021. Differences between reported and predicted incidences during the pandemic were compared using the Mann-Whitney U test.
RESULTS: Between 2013 and 2019, the incidence rate of three types of notifiable infectious diseases fluctuated between 494.05/100,000 and 550.62/100,000. No discernible trend was observed for types A and B infectious diseases (Z = -1.344, P = 0.18). A significant upward trend was observed for type C infectious diseases (Z = 2.56, P = 0.01). In 2020, the overall incidence rate of three types of notifiable infectious diseases decreased to 367.08/100,000. Compared to predicted values, the reported incidence of three types of infectious diseases was, on average, 30.05% lower in 2020 and 16.58% lower in 2021.
CONCLUSION: The public health interventions implemented during the pandemic had a positive consequence on the prevention and control of other infectious diseases, with a particularly notable effect on type C infectious diseases. Among the diseases with different transmission routes, respiratory diseases and gastrointestinal or enteroviral diseases decreased significantly.
BARACLUDE was evaluated in two clinical trials of pediatric subjects 2 years of age and older with HBeAg-positive chronic HBV infection and compensated liver disease. The exposure of BARACLUDE in nucleoside-inhibitor-treatment-naïve and lamivudine-experienced pediatric subjects 2 years of age and older with HBeAg-positive chronic HBV infection and compensated liver disease receiving 0.015 mg/kg (up to 0.5 mg once daily) or 0.03 mg/kg (up to 1 mg once daily), respectively, was evaluated in Study AI463028. Safety and efficacy of the selected dose in treatment-naïve pediatric subjects were confirmed in Study AI463189, a randomized, placebo-controlled treatment trial [see Indications and Usage (1), Dosage and Administration (2.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.2)].

There are limited data available on the use of BARACLUDE in lamivudine-experienced pediatric patients; BARACLUDE should be used in these patients only if the potential benefit justifies the potential risk to the child. Since some pediatric patients may require long-term or even lifetime management of chronic active hepatitis B, consideration should be given to the impact of BARACLUDE on future treatment options [see Microbiology (12.4)].

The efficacy and safety of BARACLUDE have not been established in patients less than 2 years of age. Use of BARACLUDE in this age group has not been evaluated because treatment of HBV in this age group is rarely required.
The invention belongs to the field of ethnic medicines and discloses a yao medicine composition for treating the hypertensive diseases and a preparation method of the Yao medicine composition. The yao medicine composition comprises the components in parts by weight: 2-20 parts of diospyros kaki L.f., 2-20 parts of altemanthera, 2-20 parts of sungh diux nzunx, 3-30 parts of gumiexu, 2-20 parts of dendranthema indicum, 3-30 parts of tairen and 2-20 parts of biouh nzimh. The yao medicine composition is powder or bagged tea. The preparation method comprises the steps of performing smashing, baking and disinfection sterilization on raw medicinal materials to prepare the powder or the bagged tea. Clinical test shows that the yao medicine composition has the effects of promoting production of body fluid, nourishing the lung, dispelling wind, reducing fire, clearing away heat and toxic materials, cooling blood, soothing liver, relieving dizziness, dispelling the effects of alcohol, realizing diuresis and reducing blood pressure, achieves the effects of health protection and hypertensive disease treatment. The yao medicine composition takes quick and stable treating effect, does not have toxic and side effects, and is a health-protection medicine with an effect of preventing and treating the hypertensive diseases.
The present invention relates to an herbal therapeutic product for controlling diabetes mellitus comprising at least one hypoglycemic compound extracted from the pulp of fruit  Eugenia jambolina . The said product is prepared from the pulp of the fruit  Eugenia jambolina  comprising cleaning and drying the fruit to remove the extraneous material from the outer layer of the said fruit, deseeding the said fruit, soaking the de-seeded pulp in water, mixing the said mixture of water and pulp and keeping it overnight in controlled cooled conditions to maintain the activity of hypoglycemic compounds, filtering the said mixture, washing the residue with water to extract all the active compounds from the said mixture of water and pulp in the form of clear watery solution, reducing the water content by keeping the said clear watery solution in freezing conditions to get the residues in concentrated form, purifying the said concentrated product in the chromatography by using slurries of different columns. Buffers are added in the said purified mixture present in the said chromatography to elute the mixture of hypoglycemic compounds. The thin layer chromatography is then conducted of the said hypoglycemic compounds in the said mixture to get the said hypoglycemic compounds in the form of bands. The said bands are exposed in the iodine chamber for the clear demarcation of the said hypoglycemic compound bands. The said hypoglycemic compounds are then extracted to get the herbal therapeutic product to control the glucose level.
The starting person will first talk about white noise and explain how he can direct breastfeeding, and fill the Informed Volunteer Form, Patient Identification Form and Application Registration Form. The mother and baby will be given the appropriate position and breastfeeding will be started. No application will be applied to the mother during the first breastfeeding. During the second breastfeeding, 30 newborn group Orhan OSMAN's "Kolik" album will be played on the music player "Your Baby Don't Cry". After the process is completed, a written response will be received for the data Premature Baby Comfort Scale, LATCH breastfeeding diagnostic measurement tool, Patient Diagnosis Form and Application Registration Form.
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease is a major public health problem considering its high prevalence and its strong association with extrahepatic diseases. Implementing strategies based on an intermittent fasting approach and supervised exercise may mitigate the risks. This study aims to investigate the effects of a 12-week time-restricted eating (TRE) intervention combined with a supervised exercise intervention, compared with TRE or supervised exercise alone and with a usual-care control group, on hepatic fat (primary outcome) and cardiometabolic health (secondary outcomes) in adults with obesity.
METHODS AND ANALYSIS: An anticipated 184 adults with obesity (50% women) will be recruited from Granada (south of Spain) for this parallel-group, randomised controlled trial (TEMPUS). Participants will be randomly designated to usual care, TRE alone, supervised exercise alone or TRE combined with supervised exercise, using a parallel design with a 1:1:1:1 allocation ratio. The TRE and TRE combined with supervised exercise groups will select an 8-hour eating window before the intervention and will maintain it over the intervention. The exercise alone and TRE combined with exercise groups will perform 24 sessions (2 sessions per week+walking intervention) of supervised exercise combining resistance and aerobic high-intensity interval training. All participants will receive nutritional counselling throughout the intervention. The primary outcome is change from baseline to 12 weeks in hepatic fat; secondary outcomes include measures of cardiometabolic health.
ETHICS AND DISSEMINATION: This study was approved by Granada Provincial Research Ethics Committee (CEI Granada-0365-N-23). All participants will be asked to provide written informed consent. The findings will be disseminated in scientific journals and at international scientific conferences.
TRIAL REGISTRATION NUMBER: NCT05897073.
Patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with both the Humphrey HFA-III perimeter and the SmartSystem VR headset on the same clinic visit, spaced roughly 10-15 minutes apart. The sequence in which each patient undertakes the two tests will be randomized. Group A includes participants who tested using the HFA, followed by a 15 minute rest period, then tested with the SSVR.
It is increasingly clear that people with schizophrenia have a range of visual perception impairments, including in low-level vision (e.g., acuity, contrast sensitivity) and mid-level vision (e.g., perceptual organization, coherent motion detection). These impairments are significantly related to poorer performance on cognitive (e.g., visual learning and memory) and social cognitive (e.g., facial emotion decoding) measures, and to worse functional outcomes. To date, there is no accepted technique for visual remediation for schizophrenia, and almost no work has been done in this area. However, visual remediation is a well-developed subfield within cognitive rehabilitation for traumatic brain injury (TBI) patients, and initial studies of short-term visual perceptual learning in schizophrenia indicate that plasticity exists that could support longer-term changes. Therefore, the overall goal of the proposed project is to test a visual remediation intervention for schizophrenia and determine its effects on specific visual targets with well-understood neurobiological mechanisms. The goal of the R61 is to determine the optimal intervention for improving the targets of contrast sensitivity (CS) and perceptual organization (PO). Extensive evidence exists for impaired CS and PO in schizophrenia. Moreover, these targets are prototypical examples of gain control and integration, respectively, which were identified by the NIMH-sponsored CNTRICS initiative as being the two core mechanisms involved in visual disturbances in the disorder. The investigators will examine two computer-based interventions. One, ULTIMEYES (UE), targets CS. The other, contour integration training (CIT), targets PO. The investigators will also examine the effects of combined treatment (UE\&CIT). An active computer-based control treatment will be included. There will be 40 sessions, with assessments after every 10 sessions (N=20/group). The R61 Specific Aim is to evaluate the effects of UE and CIT on CS and PO targets, respectively, to determine if treatment effects meet a pre-specified effect-size criterion. Results of the R61 will be used to identify the treatment (UE, CIT, or UE\&CIT) and duration (i.e., dose) that most effectively and efficiently improves the target(s). The goal of the R33 is to conduct an initial randomized controlled trial (RCT) of the optimal treatment identified in the R61. The R33 Specific Aims are to: 1) replicate and extend R61 results supporting visual target engagement in an adequately powered RCT (N=50/group); and 2) determine if visual target engagement is associated with improvements in cognition, social cognition, and functional capacity. If the R33 hypotheses are confirmed, results will inform the design of a later RCT to further explore mediators and moderators of treatment effects, and to move towards a precision medicine approach, wherein we determine which individuals are most likely to benefit from this intervention.
Baltic herring is the main catch in the Baltic Sea; however, its usage could be improved due to the low processing rate. Previously we have shown that whole Baltic herring hydrolysates (BHH) and herring byproducts hydrolysates (BHBH) by commercial enzymes consisted of bioactive peptides and had moderate bioactivity in in vitro dipeptidyl peptidase (DPP)-4 assay. In this study, we identified the hydrolysate peptides by LC-MS/MS and predicted the potential bioactive DPP-4 inhibitory peptides using in silico tools. Based on abundance, peptide length and stability, 86 peptides from BHBH and 80 peptides from BHH were proposed to be novel DPP-4 inhibitory peptides. BHH was fed to a mice intervention of a high-fat, high-fructose diet to validate the bioactivity. The results of the glucose tolerance and insulin tolerance improved. Plasma DPP-4 activities, C-peptide levels, and HOMA-IR scores significantly decreased, while plasma glucagon-like peptide-1 content increased. In conclusion, BHH is an inexpensive and sustainable source of functional antidiabetic ingredients.
This study will randomly assign eligible participants who underwent drug-eluting stent placement and have maintained the standard antiplatelet therapy for 12 months to either a control group or an intervention group. The control group will continue receiving clopidogrel monotherapy for 24 months regardless of their PRU (platelet reactivity unit) values. The intervention group will receive personalized antiplatelet therapy based on their PRU values: for non-HPR patients (PRU\<208), clopidogrel monotherapy will be continued; for HPR patients (PRU≥208), dual antiplatelet therapy will be prescribed based on clinical diagnosis at the time of stent implantation and individual patients' ischemic/bleeding risk profiles. Patients (≥50 years) who presented with acute myocardial infarction at the time of coronary intervention, and have high-risk characteristics (① ≥65 years ② multi-vessel disease ③ diabetes mellitus ④ chronic kidney disease ⑤ recurrent myocardial infarction) will receive ticagrelor 60 mg twice daily with aspirin, whereas the remainder will receive clopidogrel with aspirin. For high-bleeding-risk patients with two or more major bleeding risk factors according to ARC-HBR, the investigator may consider early discontinuation of dual antiplatelet therapy or de-escalation therapy like aspirin monotherapy based on the patient's risk profile. The treatment assignment ratio is 1:1. The study period will be up to 24 months from the time of randomization.
PROBLEM TO BE SOLVED: To obtain humectant which possesses excellent hygroscopicity and moisture retention, can exert the agreeable touch and is useful as the components of a skin cosmetic and a bathing agent by making the humectant contain a natural humectant factor of L-serine N-methylated derivative as an active ingredient. SOLUTION: This humectant comprises N-methyl serine (Preferably N-methyl- L-serine. Further, N-methyl-DL-serine or N-methyl-D-serine is also similarly usable). This moisturizer can be added into e.g. a skin cosmetic, a bathing agent or the like and is blended preferably, for example, in proportions of 0.001-10.0 wt.% based on the whole weight of the skin cosmetic and 0.01-10.0 wt.% based on the whole weight of the bathing agent to be used. As a result, the humectant having excellent hygroscopicity and humectant property is obtained and further, the skin cosmetic and the bathing agent having the agreeable touch can be provided.
The invention is an apparatus and method for the treatment of bacterial diseases based on the antibacterial characteristic of the electrically released silver ions. The method includes the implantation of a small electrode including silver in the infected bone, embedding another small electrode including another metallic element subcutaneously, and initiating the release of silver ions by applying a small current between the two electrodes. The initiation current is applied for a very short time and then discontinued. After this a continuous release of the silver ions will take place for a long time while spreading the silver ions to the surrounding tissue as well. This process assures a long-term antibacterial effect, which after accomplishing the infection healing will also provide preventive care. The apparatus comprises all of the components necessary to carry out the method.
Detecting illness onset of a user based on IoT data is provided. Onset of an illness affecting the user is detected based on analyzing data regarding the user collected from a plurality of IoT devices corresponding to the user. Crowdsourced data is collected from a defined area surrounding a geolocation of the user. The crowdsourced data is related to the illness and includes a median illness duration and severity for the illness. An illness history of the user is collected from a profile corresponding to the user. Criticality of upcoming events is identified in an electronic calendar corresponding to the user. A recommended course of action for the user regarding the illness is calculated based on the crowdsourced data from the defined area surrounding the geolocation of the user, the illness history of the user, and the criticality of upcoming events corresponding to the user.